Indiana University School of Medicine, Department of Biochemistry and Molecular Biology, 635 Barnhill Dr., Indianapolis, IN 46202, United States.
The University of Arizona, College of Pharmacy, Department of Pharmacology and Toxicology, 1703 E. Mabel St., PO Box 210207, Tucson, AZ 85721, United States.
Bioorg Med Chem. 2022 Dec 1;75:117072. doi: 10.1016/j.bmc.2022.117072. Epub 2022 Oct 30.
While many studies have established the importance of protein homeostasis in tumor progression, little effort has been made to examine the therapeutic potential of targeting the HSP60 chaperonin system. In healthy cells, HSP60 is localized to the mitochondrial matrix; however, emerging evidence indicates HSP60 can be over-expressed and mis-localized to the cytosol of cancer cells, which is hypothesized to promote tumor cell survival and proliferation. This opens a potential avenue to selectively target the aberrant HSP60 in the cytosol as a chemotherapeutic strategy. In the present work, we examined a series of bis-aryl-α,β-unsaturated ketone (ABK) HSP60 inhibitors for their ability to selectively target cancerous vs non-cancerous colon and intestine cells. We found that lead analogs inhibited migration and clonogenicity of cancer cells, with cytotoxicity correlating with the level of aberrant HSP60 in the cytosol.
虽然许多研究已经确定了蛋白质动态平衡在肿瘤进展中的重要性,但很少有人努力研究靶向 HSP60 伴侣蛋白系统的治疗潜力。在健康细胞中,HSP60 定位于线粒体基质;然而,新出现的证据表明,HSP60 可以过度表达并错误定位到癌细胞的细胞质中,这被假设可以促进肿瘤细胞的存活和增殖。这为选择性靶向细胞质中异常的 HSP60 作为一种化疗策略开辟了一个潜在途径。在本工作中,我们研究了一系列双芳基-α,β-不饱和酮(ABK)HSP60 抑制剂,以评估它们选择性靶向结肠和肠道癌细胞的能力。我们发现,先导类似物抑制癌细胞的迁移和集落形成能力,细胞毒性与细胞质中异常 HSP60 的水平相关。